Table 7.
Incidence of overall treatment‐related adverse events (TRAEs) and grade ≥3 TRAEs occurring in ≥10% of patients with non‐small‐cell lung cancer treated with ASP8273 (phase II) at initial dose level (safety analysis set)
| 300 mg (N = 76) | ||
|---|---|---|
| All grades, n (%) | Grade ≥3, n (%) | |
| Overall | 71 (93) | 29 (38) |
| Constipation | 9 (12) | 0 (0) |
| Diarrhea | 43 (57) | 0 (0) |
| Nausea | 20 (26) | 0 (0) |
| Vomiting | 21 (28) | 0 (0) |
| Malaise | 10 (13) | 0 (0) |
| Alanine aminotransferase increased | 22 (29) | 3 (4) |
| Aspartate aminotransferase increased | 13 (17) | 2 (3) |
| Platelet count decreased | 13 (17) | 0 (0) |
| Decreased appetite | 12 (16) | 3 (4) |
| Hyponatremia | 22 (29) | 15 (20) |
| Dysgeusia | 9 (12) | 0 (0) |
| Hypoesthesia | 8 (11) | 0 (0) |
| Peripheral sensory neuropathy | 18 (24) | 0 (0) |
| TRAEs of special interest | ||
| Rash | 5 (7) | 0 (0) |
| QTc prolongation | 5 (7) | 0 (0) |
| Interstitial lung disease | 0 (0) | 0 (0) |